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ABSTRACT
Myocyte enhancer factor 2 (MEF2) proteins play a
key role in promoting the expression of muscle-
specific genes in differentiated muscle cells. MEF2
activity is regulated by the association with several
transcriptional co-factors and by post-translational
modifications. In the present report, we provide
evidence for a novel regulatory mechanism of
MEF2C activity, which occurs at the onset of
skeletal muscle differentiation and is based on
Lys4 acetylation. This covalent modification results
in the enhancement of MEF2C binding to DNA and
chromatin. In particular, we report that the kinetic
parameters of MEF2/DNA association change sub-
stantially upon induction of differentiation to give a
more stable complex and that this effect is mediated
by Lys4 acetylation. We also show that Lys4
acetylation plays a prominent role in the p300-
dependent activation of MEF2C.
INTRODUCTION
The myocyte enhancer factor 2 (MEF2) transcriptional
activators are members of the MADS box (MCM1,
Agamous and Deﬁciens, SRF) family of proteins. There
are four vertebrate MEF2 proteins, MEF2A, B, C and D,
encoded by distinct genes. They share high amino acid
identity (95%) throughout the highly conserved amino-
terminal MADS box (aa 1–57) and the adjacent MEF2-
speciﬁc domain (aa 58–86); these domains mediate
the DNA-binding aﬃnity and speciﬁcity and the homo
and hetero dimerization (1). The C-terminal region
of MEF2 proteins is more divergent and acts as a
transcriptional activation domain. MEF2 factors were
originally identiﬁed in skeletal muscle cells, they lack
myogenic activity, but strengthen the activity of myogenic
bHLH proteins. Several lines of genetic and biochemical
evidence underscore the central role played by MEF2
proteins in promoting skeletal muscle diﬀerentiation.
Loss-of-function mutations in the single Drosophila
MEF2 gene prevent myoblast diﬀerentiation (2–4) and
dominant-negative MEF2 mutants inhibit myoblast dif-
ferentiation in vitro (5). The pivotal role played by MEF2
proteins in skeletal myogenesis has been reinforced by two
recent papers where the role of MEF2 proteins in
vertebrate skeletal muscle in vivo has been clariﬁed. The
combined knock down of mef2c and mef2d in zebraﬁsh
revealed the essential role of MEF2 proteins for thick
ﬁlament formation after terminal diﬀerentiation (6).
Similar results were obtained in mice where skeletal
muscle-speciﬁc mef2c deletion results in sarcomere dis-
organization and myoﬁbres deterioration after birth (7).
The transcriptional activity of MEF2 is tightly regu-
lated during skeletal muscle diﬀerentiation. MEF2 pro-
teins are expressed in proliferating C2C12 myoblasts but
they fail to activate MEF2-dependent transcription of
endogenous or transiently transfected genes unless the
cells are induced to diﬀerentiate (8,9). Multiple pathways
exist to ensure the repression of these transcription factors
in dividing myoblasts. For example, Cdk4/Cyclin D
represses the activity of MEF2 proteins by blocking
their interactions with GRIP1 (10). In C2C12 myoblasts
repression of MEF2 activity depends on its association
with class II HDACs-4-5-7-9 (11). This interaction does
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not aﬀect MEF2 DNA-binding activity and implies the
recruitment of HDACs to MEF2-containing transcrip-
tional complexes.
During muscle diﬀerentiation, class II HDACs are
sequestered in the cytoplasm. As a result, transcriptional
repression by HDACs is relieved, leading to up-regulation
of MEF2 target genes, such as ‘Muscle Creatine Kinase
(MCK)’. Release of class II HDACs from MEF2 may
occur by phosphorylation of conserved serine residues in
the HDAC N-terminal region, resulting from the activa-
tion of number of Ser/Thr kinases such as CaMK, PKCd,
PKD, MARK2, Mirk/dyrk1B and SIK1 serine/threonine
kinases (12–14). The released MEF2 is then able to
associate with the acetyltransferase co-activator p300 and
stimulate MEF2-dependent genes. Importantly, MEF2
activity is regulated by several post-translational modiﬁ-
cations in the C-terminal region: MEF2C is acetylated by
the histone acetyltransferase (HAT) p300 selectively in
diﬀerentiated muscle cells and this post-translational
modiﬁcation enhances MEF2 activity (15). Moreover,
MEF2 proteins are sumoylated in vitro and in vivo on a
C-terminal lysine residue and this post-translational
modiﬁcation inhibits their transcriptional activity, likely
through the recruitment of transcriptional repressors
other than class II HDACs (16–19).
In the present report, we contribute to the under-
standing of the mechanisms underlying the activation of
MEF2 proteins in diﬀerentiating muscle cells, by provid-
ing evidence of a regulation of the DNA-binding proper-
ties of MEF2C. In particular, we describe for the ﬁrst time
a diﬀerentiation-dependent post-translational modiﬁca-
tion that occurs in the MADS box, consisting of lysine 4
acetylation. This modiﬁcation results in the enhancement
of the binding of MEF2C to its cognate DNA site, as well
as of its transcriptional activity. In addition, we ﬁnd
evidences for p300 playing a role in this regulatory
mechanism: p300 enhances the DNA-binding activity of
MEF2 and acetylates it on Lys4, furthermore, Lys4
acetylation contributes substantially to the p300-mediated
activation of MEF2-dependent transcription.
MATERIALS AND METHODS
Plasmids
The bacterial expression vector pET32b/MEF2C was
generated by subcloning a PCR product of the mouse
MEF2C cDNA in the pET32b(+) vector (Novagen),
resulting in fusion of His6-thioredoxin with MEF2C
(His6MEF2C). Brieﬂy, the cDNA encoding MEF2C [gi:
293728] was ampliﬁed from pcDNAI/Amp/MEF2C, using
the following primers:
TA_FW 50-GGGAAGCTTGGGAGAAAAAAGAT-30
TA_REV 50-TCTAGATCATGTTGCCCATCCTTC-30.
The PCR product was inserted in the pCR3.1 vector
using the TA cloning kit (Invitrogen). The insert was
excised from pCR3.1 by cutting with HindIII/NotI
restriction enzymes and inserted in the same restriction
sites in the pET32b(+) plasmid vector.
The expression vector pET32b/MEF2C1-92 was
obtained by deleting the DNA sequence encoding the
amino acids 93–466 of MEF2C from the pET32b/MEF2C
plasmid by site-directed mutagenesis with the Quick
Change Site-Directed Mutagenesis Kit (Stratagene). The
deleted plasmid was obtained by PCR ampliﬁcation of
pET32b/MEF2C with the following oligonucleotides:
FW 50-GAGAAAGAAGGGCCTCGCGGCCGCACTC
GAGC-30
RV 50-GCTCGAGTGCGGCCGCGAGGCCCTTCTTT
CTC-30
pcDNAI/Amp/MEF2C_K4R, pcDNAI/Amp/MEF
2C_K4Q, pGFP/MEF2C_K4R, pGFP/MEF2C_R3T
and pFLAG/MEF2C_K4R, pET32b/MEF2C1-92_K4R
were obtained by mutagenesis respectively of pcDNAI/
Amp/MEF2C (20), pGFP/MEF2C, pFLAG/MEF2C
(21) and pet32b/MEF2C1-92. The mutagenesis reactions
were performed using the Quick Change Site-Directed
Mutagenesis Kit (Stratagene). The plasmid encoding
the HA-tagged p300 (22) was a generous gift of Pier
Lorenzo Puri (Dulbecco Telethon Institute at Fondazione
A. Cesalpino, Rome, Italy). The reporter plasmid
for MEF2-dependent transcription, pGL3(desMEF2)3,
contains three tandem MEF2 sites from the mouse
Desmin enhancer (23) inserted in the pGL3 vector
(Promega) and was a kind gift of S. Schiaﬃno
(University of Padova, Italy).
Cell cultures and transfections
C2C7 is a skeletal muscle cell line subcloned (24) from
the original C2 cell line derived from C3H mice (25). This
cell line was kindly provided by M. Buckingham (Pasteur
Institute, Paris, France). C2C7 cells were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM,
Euroclone) containing 20% fetal calf serum (FCS, Life
Technologies) (Growth Medium, GM) at low density and,
when approaching conﬂuence, induced to diﬀerentiate
with DMEM–2% Horse Serum (HS, Hyclone)
(Diﬀerentiation Medium DM). COS1 simian kidney cells
(26) and C3H10T1/2 mouse ﬁbroblasts were maintained in
DMEM containing 10% FCS. Cells, grown at 80%
conﬂuence, were transfected using the lipid-based
Lipofectamine Plus Reagent (Invitrogen) according to
the manufacturer’s instructions. For confocal imaging,
cells were grown in glass-bottom Petri dishes (WillCo).
C3H10T1/2 myogenic conversion assay
C3H10T1/2 cells were grown to 60% conﬂuence in
60-mm dishes and transfected with Lipofectamine-Plus
reagent (Invitrogen) with 3 mg of pEMSV-MyoD (27)
in association with 1 mg of pcDNAI/Amp (empty
vector), pcDNAI/Amp/MEF2C and pcDNAI/Amp/
MEF2C_K4R. After 24 h, cells were split in 40-mm
dishes and mantained in growth medium for 24 h and
then transferred to diﬀerentiation medium changing
media every 2 days. Myogenic conversion was assessed
by western blot analysis of Myosin heavy chain (MyHC)
expression. Cells were harvested at diﬀerent time points
and lysed in 100 ml of single detergent buﬀer [50mM Tris–
HCl pH 8, 150mM NaCl, 1% Triton X-100 supplemented
with protease inhibitors (Roche)]. The extracts were
analysed by western blotting, using the antibodies
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against actin and MyHC. The results were quantitated by
densitometry.
Transcription reporter assays
COS1 cells were co-transfected with pGL3(desMEF2)3,
pRSVb-gal, the expression vectors for MEF2C wild-type
(WT) or MEF2C mutant (K4R) and for the HA-tagged
p300 enzyme. Thirty-six hours after transfection, cell
lysates were obtained by three freeze-and-thaw cycles in
250mM Tris–HCl pH 7.5, 15% glycerol and 10mM
Dithiothreitol (DTT); 30% of the extract was used for the
b-galactosidase assay and up to 30% for the luciferase
assay. For the luciferase assay, samples were diluted to a
350 ml volume with LUC buﬀer (25mM Glycil–glycine pH
7.8, 2mM ATP, 10mM MgSO4) and incubated with
40-nm Luciferin (Sigma). Luciferase activity was mea-
sured in the luminometer LUMAT LB 9501; Berthold.
For the b-galactosidase assay samples were processed as
described previously (28). Luciferase activity was normal-
ized to the b-galactosidase activity.
Protein analysis
Samples were diluted in 1 SDS gel-loading buﬀer
(50mM Tris–HCl pH 6.8, 100mM DTT, 2% SDS, 0.1%
bromophenol blue, 10% glycerol) and separated by SDS-
polyacrylamide gel electrophoresis (SDS–PAGE). The
separated proteins were subsequently analysed by western
blot as previously described (21). The following antibodies
were used: mouse M2 monoclonal anti-FLAG (1:1000,
F3165, Sigma), rabbit polyclonal anti-Acetylated-Lysine
(1:1000, #9441, Cell Signaling), rabbit polyclonal anti-
MEF2 (1:5000, C21 sc-313X, Santa Cruz), mouse mono-
clonal anti-His6 (1:500, #11922416001, Roche), rabbit
polyclonal anti-actin (1:1500, #MAB 1501, Chemicon)
and mouse monoclonal anti MyHC (1:200, MF20
Developmental Studies Hybridoma Bank, IA, USA).
Chromatin immunoprecipitation (ChIP)
and PCR amplification
The ChIP protocol was performed on C2C7 cells as
described (29). C2C7 cells were grown in GM. At 90% of
conﬂuence (0 h), they were induced to diﬀerentiate in DM
for 24 h. The following antibodies were used: rabbit
polyclonal anti-MEF2 (C21 sc-313X, 200mg/0.1ml,
Santa Cruz) and, as a control, goat polyclonal anti-
enolase (C-19 sc-7455, 200mg/m1, Santa Cruz).
Precipitated DNA fragments were analysed by semi-
quantitative PCR with BD Advantage TM 189 2 PCR Kit
(BD Biosciences). Immunoprecipitated DNA was sub-
jected to 28 cycles of PCR with primers speciﬁc for the
Myogenin promoter (sense 50-TTTCTGTGGCGTTGGC
TATATATTTATC-30; antisense 50-TGCTGGGTGCC
ATTTAAAC-30) or for an enhancer region of the liver-
speciﬁc Phenylalanine Hydroxylase (PAH) gene (30) (sense
50-CAAAATGGTGCTGTATCTCTGATATTC-30, anti-
sense 50-GGCACCAACTTCCTCTTTGAGT-30). As a
control for DNA content, PCR reactions were also
performed on chromatin samples prior to immunopreci-
pitation (input), undiluted or diluted by a factor of 50, 100
and 200 to assess whether the assay is being performed
in the linear range. The resulting PCR products were
resolved through a 10% native acrylamide gel and DNA
visualized by Ethidium Bromide staining. The immuno-
precipitated chromatin was quantiﬁed by real-time quan-
titative PCR with an ABI 7900 PRISMTM DNA Sequence
Detector (PE Applied Biosystems) using a SYBR GREEN
PCR Core Reagent Kit (PE Applied Biosystems). The
chromatin was subjected to 40 ampliﬁcation cycles.
Known quantities of total input were used as standards.
Fold enrichment was estimated relative to the control
antibody sample.
Fluorescence recovery after photobleaching (FRAP)
FRAP experiments were performed on a Leica TCS SP2
confocal laser scanner microscope using a 63X/1,4N.A.
oil immersion objective. Transfected C2C7 cells, expres-
sing the ﬂuorescent fusion proteins GFP-MEF2C_WT,
K4R or R3T, were excited with an Argon laser at 488 nm.
Images were collected every 0.064 s at a resolution of
512  64 pixels as follows: 5 images for pre-bleaching,
5 images for bleaching, 150 images for post-bleaching.
Bleaching was performed using the 488 nm and 514 nm
lines of an Ar laser at 100% laser power (100mW total
nominal output) on a circular region of 3-mm diameter;
recovery was observed with low laser intensity. In order to
correct for the loss in ﬂuorescence during the acquisition,
data were doubly normalized as described previously
(31,32). For each experiment, at least 10 datasets were
collected, which were used to calculate the half-life of
maximal recovery. This is deﬁned as the time point after
bleaching when the normalized ﬂuorescence has increased
to half the value of maximal recovery. Each experiment
was repeated at least twice.
Nuclear extracts and electrophoretic mobility
shift assays (EMSAs)
The nuclear extracts of COS1 cells ectopically expressing
MEF2C_WT or K4R and C2C7 cells were obtained as
described previously (21). The double-stranded probe,
representing the MCK MEF2-binding site, was obtained
by in vitro annealing of complementary oligonucleotides.
Terminal labelling was obtained by incubation with
polynucleotide kinase (PNK) in the presence of
[g-32P]ATP. The sequences of the sense strands of the
probes, wt or mutant, were as described previously (33).
EMSAs were performed as described (34). The binding
reaction was performed in a total volume of 15 ml
containing 4 mg of nuclear extract proteins and 1 ng of
labelled DNA probe. Alternatively, the labelled MEF2-
binding site was incubated with 4 ml of the in vitro
translated proteins MEF2C_WT or MEF2C_K4R and
MEF2C_K4Q. Where indicated the C2C7 cells nuclear
extracts were added with 0.5 ml of p300 enzyme obtained
in the baculovirus system (35). In vitro translated proteins
were obtained with the TnT Quick Coupled
Transcription/translation System (Promega). p300 was a
generous gift of Roberto Mantovani (University of
Milano). For the supershift experiments, 0.2 ml of
MEF2 antibody (C21 sc-313X, Santa Cruz) was used.
Competition experiments were performed by diluting the
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labelled probe with a 100-fold molar excess of cold wt or
mutant competitor probe.
Purification of bacterially expressed recombinant proteins
The recombinant proteins His6MEF2C1-92_WT or K4R
were puriﬁed from transformed BL21 bacterial cells.
Expression of the recombinant proteins was induced
with 1mM isopropyl-b-D-thiogalactopyranoside (IPTG)
for 3 h at 378C. Recombinant proteins were aﬃnity
puriﬁed with a Ni-NTA Agarose (Qiagen) according to
the manufacturer’s instructions.
In vitro acetylation assay
One microgram of bacterially expressed protein was
incubated with 0.5 ml of baculovirus-puriﬁed p300 for 1 h
at 308C in a 30-ml reaction mixture containing acetylation
buﬀer (50mM Tris–HCl pH 8.5, 0.1mM EDTA, 10%
glycerol, 1mM DTT, 10mM sodium butyrate, 1mM
PMSF) and 1mM acetyl coenzyme A (AcCoA). Mock
acetylation reactions were performed using AcCoA in the
absence of p300 or incubating the complete reaction mix
with the p300-speciﬁc inhibitor LysCoA (100 nM). The
p300 selective inhibitor LysCoA (36) was a generous gift
of Phil Cole (Johns Hopkins University, Baltimore).
Acetylated proteins were analysed in western blot with
an antibody that recognizes acetylated lysine residues and
successively with an antibody directed against the His6
protein tag.
Protein purification andMALDI-TOFMS analysis
One day prior to transfection, C2C7 myoblasts were plated
at a density of 106 cells/dish. Four micrograms of plasmid
expressing FLAG-MEF2C were used to transfect 10-cm
diameter dishes. Cells were maintained in growth medium
for 36 h or alternatively in diﬀerentiation medium for 72 h.
Cells were washed twice with PBS and incubated for 30min
at 48C in 1ml of lysis buﬀer [50mM Tris–HCl, pH 7.4,
150mM NaCl, 1mM EDTA, 0.1% Igepal, supplemented
with 1mM PMSF, 330 nM TSA, 10mM sodium orthova-
nadate and protease inhibitors tablet (Complete; Roche)].
FLAG-MEF2C was puriﬁed by aﬃnity gel chromatogra-
phy with the anti-FLAG M2-aﬃnity gel (Sigma), accord-
ing to the manufacturer’s instructions. Proteins recovered
from the aﬃnity columns were separated by SDS–PAGE
and then visualized by Coomassie brilliant blue staining
(Sigma). The band corresponding to FLAG-MEF2C was
excised and cut into small pieces of 1mm3. Gel pieces
were washed, reduced with DTT, S-alkylated with
iodoacetamide, and in-gel digested with trypsin (from
bovine pancreas, unmodiﬁed, sequencing grade, Roche) as
described elsewhere (37). The digestion was allowed to
proceed overnight at 378C. Digested aliquots were
analysed directly or after a desalting/concentration step
on mZipTipC18 (Millipore) before MALDI-MS analysis.
One microlitre of the sample was mixed (1:1, v/v)
with matrix (a saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% acetonitrile/0.1% TFA),
spotted onto the MALDI target and analysed by using
a Voyager-DE STR mass spectrometer (Applied
Biosystems). The search program ProFound, developed
by The Rockefeller Mass Spectrometry Laboratory and
the New York University (New York, NY), was used for
database searches (38). Peptides were selected in the mass
range of 700–4500 kDa. Spectra were calibrated using a
matrix and tryptic autodigestion ion peaks as internal
standards.
Multiple sequence alignment
Amino acid sequences of mouse MEF2C [gi:293728],
human MEF2C [gi:2500875], mouse MEF2A
[gi:2500873], human MEF2A [gi:1170908], mouse
MEF2D [gi:19526812], human MEF2D [gi:2500876],
mouse MEF2B [gi:6678852], human MEF2B
[gi:5174543], Drosophila MEF2 [gi:25453445], DEFI-
CIENS [gi:118426], AGAMOUS [gi:399096], Saccharo-
myces cerevisiae MCM1 [gi:6323686], SRF_human
[gi:134876] were aligned with Clustal W.
RESULTS
MEF2 binds the regulatory region of theMyogenin gene
and increases its residence time on chromatin in C2C7
cells upon induction of muscle differentiation
In proliferating C2C7 myoblasts, MEF2 proteins are
expressed but are transcriptionally silent (8,9). To
investigate whether MEF2 proteins change their binding
properties to DNA during muscle cell diﬀerentiation, we
performed ChIP experiments (Figure 1A–C) on the
chromatin extracted from proliferating C2C7 cells cul-
tured in high serum (GM) or cells stimulated to
diﬀerentiate in low serum for 24 h (DM). Speciﬁcally, we
veriﬁed the enrichment of the regulatory region of the
Myogenin gene in the chromatin immunoprecipitated
by the MEF2 antibody versus the control antibody, by
PCR ampliﬁcation of the DNA region encompassing
nucleotides from 82 to 14 (Figure 1A, upper panel).
The enhancer region of the liver-speciﬁc PAH gene
(Figure 1A, lower panel) was used as a control.
Equivalent amounts of input chromatin were used for
each sample as shown in Figure 1B (upper and lower left
panels). PCR reactions were conducted in semi-quantita-
tive conditions (Figure 1B, upper and lower right panels).
The MEF2 antibody immunoprecipitates a complex where
theMyogenin sequence is enriched, in comparison with the
background level seen with control antibody, only in
diﬀerentiated muscle cells. (Figure 1A, upper panel, lane 3
compared to control lane 4). The presence of MEF2
proteins in the immunoprecipitates of C2C7 cells at both
stages was conﬁrmed by western blot analysis (data not
shown).
No signiﬁcant binding of MEF2 to the Myogenin
control region could be detected at the myoblast
stage (Figure 1A, upper panel, lane 1 compared to control
lane 2). A similar enrichment for the PAH control
sequence was not observed (Figure 1A, lower panel).
The above results were conﬁrmed by a quantitative real-
time PCR ampliﬁcation of the Myogenin and PAH
regulatory regions from the immunoprecipitated chroma-
tin. Results in Figure 1C show a signiﬁcant higher
recruitment of MEF2 proteins to the promoter of the
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Myogenin gene in diﬀerentiated muscle cells than in
myoblasts; in contrast, the level of MEF2 proteins
recruitment to the enhancer of the PAH gene is negligible
both in proliferating and in diﬀerentiating C2C7 muscle
cells. These data show that MEF2 proteins bind the
Myogenin promoter in myotubes but not in myoblasts.
Myogenin is an early muscle-speciﬁc gene, whose
mRNA starts to be detected 24 h after induction of
muscle diﬀerentiation in C2C7 cells. In addition, the
expression of the Myogenin gene is entirely dependent,
in vitro, on the integrity of the MEF2 site in its proximal
regulatory region (9).
The ability of a transcription factor to activate the
transcription of its target genes depends in part on its
DNA-binding aﬃnity. ChIP experiments enable the
analysis of a ﬁxed binding situation. In fact, due to
formaldehyde cross-linking, changes in key kinetic para-
meters of DNA–protein interactions, like the ‘oﬀ-rate’,
are evened up. Therefore, we explored the dynamic and
kinetic properties of the MEF2–DNA interactions in
proliferating and diﬀerentiating C2C7 cells ectopically
expressing the GFP-MEF2C fusion protein, using the
technique of FRAP (Figure 1D and E). The FRAP
technique allows the measurement of the mobility of a
protein in a living cell, this parameter contains informa-
tion about the in vivo binding properties of a protein, the
main determinant of the intranuclear mobility of tran-
scription factors is their ability to bind DNA (32,39).
First, we veriﬁed that the tagged protein GFP-MEF2C
binds DNA and activates transcription of a MEF2-driven
reporter gene with an eﬃciency which is comparable to wt
MEF2C (data not shown). The representative image of a
FRAP experiment shown in Figure 1C, indicates that
GFP-MEF2C localizes homogenously throughout the
nucleus and is excluded from the nucleolus. Fluorescence
bleaching was obtained by applying maximal laser power
to a selected circular region of the nucleus (Figure 1D, 0 s,
pre-bleaching); ﬂuorescence recovery in the bleached area
was then determined at the indicated time intervals
(Figure 1E). The relative ﬂuorescence of the bleached
area (ﬂuorescence in the bleached area corrected for the
change in total nuclear ﬂuorescence) in myoblasts and in
diﬀerentiating myotubes as a function of time is reported
in Figure 1E. It is evident that recovery after bleaching is
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Figure 1. Analysis of MEF2 association to its cognate sites on chromatin in proliferating and diﬀerentiating C2C7 muscle cells. (A) Soluble
chromatin prepared from proliferating myoblasts cultured in growth medium (GM) or conﬂuent cells cultured in diﬀerentiation medium for 24 h
(DM), was processed for ChIP assays with the antibody directed against MEF2 (MEF2 Ab, lanes 1 and 3) or anti-enolase as a control antibody
(lanes 2 and 4). PCR products, obtained with primers spanning the MEF2 site in the Myogenin regulatory region (nt 82 to 14, upper panel), or a
region of the promoter of the liver-speciﬁc gene PAH (lower panel), were analysed by gel electrophoresis. (B) Equivalent amounts of INPUT
chromatin were used as shown by direct PCR of the chromatin samples (lanes 1 and 2). Dilutions (1:50, 1:100; 1:200) of the input DNA from
proliferating muscle cells were subjected to PCR in order to verify if the reaction is being performed in semi-quantitative conditions.
(C) Quantiﬁcation of the Myogenin promoter and PAH enhancer immunoprecipitated in the ChIP assays described above using SYBR green and
real-time PCR. The quantities of DNA fragments immunoprecipitated with the MEF2 antibody are shown as fold the quantity precipitated with the
control antibody, this quantity was arbitrarily taken as 1. The results shown are the averageSE of at least three estimations. (D, E) FRAP analysis
of GFP-MEF2C. C2C7 cells were transfected with GFP-MEF2C and maintained in growth medium (GM) or switched to low serum for 24 h (DM).
(D) Time laps imaging of a nucleus, maximal laser power was applied to a selected nuclear area (circle). The recovery of ﬂuorescence in the bleached
area was imaged at the indicated time points (0.7, 2 and 10 s; 0 s is the image taken before bleaching) (Bar: 1 mm). (E) Fluorescence intensities in the
bleached regions were quantiﬁed and corrected for the change in total ﬂuorescence. The obtained relative ﬂuorescence values were plotted against
time. Bleaching was at t=0.
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slower in diﬀerentiating muscle cells than in myoblasts.
The plot was also used to determine the t1/2 of recovery
(protein ﬂuorescence half-life). Since the recovery of
ﬂuorescence in the bleached area is due to the migration
of unbleached molecules from the surroundings of the
bleached area, the protein ﬂuorescence half-life can be
considered a measure of the mobility of the protein and
therefore of its association to chromatin. As it is shown in
Figure 5D, the t1/2 of GFP-MEF2C in myoblasts is 0.34 s
(0.03 s SE) versus a t1/2 of 0.64 s (0.05 s SE) measured
in cells induced to diﬀerentiate. The ChIP and the FRAP
results strongly suggest an increase of the aﬃnity of
MEF2C for its chromatin sites in response to a
diﬀerentiation stimulus, concomitant with the activation
of MEF2-dependent gene expression.
MEF2C is acetylated in theMADS box at Lys4 in
differentiated muscle cells
The results of the ChIP and the FRAP experiments
indicate that the stability of MEF2–DNA interaction
increases considerably at the transition from proliferating
to diﬀerentiated C2C7 muscle cells, suggesting the
existence of a regulatory mechanism that modulates the
DNA-binding activity of MEF2 in the course of myogen-
esis. Since MEF2 proteins are subjected to extensive post-
translational modiﬁcations that in some cases were shown
to regulate their activity, we undertook a systematic
analysis of MEF2C puriﬁed from proliferating or
diﬀerentiated C2C7 muscle cells, with the aim of identify-
ing diﬀerentiation-speciﬁc covalent modiﬁcations that
could account for the activation of MEF2C upon
induction of diﬀerentiation. The mass spectrometry
analysis of the tryptic digest of FLAG-MEF2C, puriﬁed
from transfected C2C7 myoblasts and myotubes, revealed
an ion peak (1273.7 kDa), which is present only in
diﬀerentiated cells (Figure 2A, compare upper and lower
panels). The mass of this ion does not correspond to any
of the theoretical peptides and is coherent with the
addition of two acetyl groups to the N-terminal part of
the recombinant protein, which includes the six
C-terminal amino acids of the FLAG peptide and the
amino acids from 2 to 5 in the native MEF2C sequence
(Figure 2, panel B; see also the alignment between the
N-terminal sequences of FLAG-MEF2C and of native
MEF2C in Figure 2C). This N-terminal fragment contains
three hypothetical acetyl acceptor lysine residues; one in
the FLAG peptide and two in the MEF2C sequence,
corresponding to Lys4 and Lys5. Since the acetylated
peptide observed in the mass spectrum results from the cut
after Lys5 and trypsin cuts proteins in correspondence of
unmodiﬁed lysine residues, we can exclude the acetylation
of Lys5 and infer that Lys4 in MEF2C and the lysine
residue in the C-terminus of the FLAG epitope are the
acetylated amino acids in the peptide. The peak corre-
sponding to the unmodiﬁed peptide was not revealed,
neither in the tryptic digest of the protein puriﬁed from
myoblasts. A simple explanation is that this region is
highly enriched of basic amino acids, which are recognized
by trypsin if not covalently modiﬁed; thus, a complete
tryptic digestion would produce peptides too small to be
reliably detected by mass spectrometry. The described
1273.7-kDa peptide could not be subjected to MS/MS
sequence analysis due to its very low relative concentra-
tion. As shown in Figure 2C, Lys4 is conserved in all
MEF2 proteins, including D-MEF2, but is absent from all
the other members of the MADS box family of transcrip-
tion factors. Although we did identify many other
modiﬁed peptides (i.e. phosphopeptides), all of them
were present in both proliferating and diﬀerentiated cells
(data not shown). Finally, we could not reliably detect
acetylated peptides other than the one containing Lys4.
Lysine 4 inMEF2C is acetylated both in vitro and in vivo
A previous report (15) described several acetylated lysine
residues in the C-terminal domain of MEF2C, notably
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Figure 2. Identiﬁcation of a novel acetylation site in MEF2C.
(A) MALDI spectra (range 1265–1290 kDa) of FLAG-MEF2C tryptic
digests obtained from transfected C2C7 myoblasts (Mb, upper panel)
and myotubes (Mt, lower panel). The monoisotopic peaks at
1275.7 and 1273.7 kDa are indicated. (B) A table is shown indicating
the mass of the monoisotopic ions (MH+), the residues range (from aa
to aa), the theoretical molecular weight (Th MH+), the sequence of
unmodiﬁed peptides and compatible modiﬁcations. The residues
amenable to the indicated modiﬁcations are underlined. (C) Sequence
comparison between the MADS box of MEF2 proteins and of other
members of the MADS box family. The lysine 4 residue is highlighted.
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only in diﬀerentiated C2C7 muscle cells. Our mass
spectrometry results indicate an additional acetylation
event that takes place on Lys4. With the aim to get
more details about the acetylation of this residue, we
performed in vitro acetylation assays. p300 puriﬁed from
baculovirus was incubated with a puriﬁed recombinant
His6-thioredoxin-fusion protein containing the N-terminal
MADS box and MEF2 domain of MEF2C WT or a
mutant where Lys4 was changed to arginine (K4R), an
amino acid that cannot be acetylated. The incorporation
of AcCoA was monitored with the antibody that
recognizes acetylated lysine residues. As shown in
Figure 3A, the acetylation of MEF2C depends on the
presence of the enzyme (compare lanes 2 and 1) and on its
catalytic activity, since the p300-speciﬁc inhibitor LysCoA
abolishes the reaction (compare lanes 2 and 3). The extent
of acetyl incorporation in the mutant protein is negligible
in comparison with the wt protein (compare lanes 5 and 2)
indicating that Lys4 is indeed a target of acetylation by
p300 in vitro. Comparable amounts of protein substrates
were used, as shown in Figure 3A, lower panel.
Importantly, we found that Lys4 is acetylated also in
cultured cells. To show this, we ectopically expressed
FLAG-MEF2C_WT or FLAG-MEF2C_K4R together
with GFP-p300 in COS1 cells. The FLAG fusion proteins
were puriﬁed by aﬃnity gel chromatography from cell
lysates 48 h after transfection and then detected with the
antibodies directed to the FLAG peptide and to acetylated
lysine. The results shown in Figure 3B demonstrate that
MEF2C is acetylated in vivo in COS1 transfected cells that
overexpress p300 and that Lys4 is one of the prominent
acetylated residues, since the signal of FLAG-
MEF2C_K4R is lower than FLAG-MEF2C_WT (at
least 30% lower as evaluated by densitometric analysis,
data not shown). The signal associated to the K4R mutant
is not abolished, consistently with the observation that
other acetylated residues are present in the full-length
protein (15).
Acetylation of Lys4 enhances the DNA-binding
activity ofMEF2C
EMSA assay. The crystal and the solution structures of
MEF2 dimers bound to DNA revealed that Lys4 is
involved in contacting DNA in the minor groove (40,41).
Since acetylation neutralizes the positive charge of Lys
e-amino groups, we sought to determine how the
acetylation of Lys4 aﬀects the interaction of MEF2 with
DNA. To investigate this, we performed EMSA experi-
ments with a 32P-radiolabelled oligonucleotide represent-
ing the MEF2 site from the enhancer of the MCK gene.
The binding reactions were performed by incubating the
labelled DNA probe with in vitro translated MEF2C
proteins (Figure 4A) or the nuclear extracts of cells
ectopically expressing MEF2 proteins (Figure 4B). We
examined the DNA-binding properties of wt MEF2C and
of the mutant proteins MEF2C_K4R and MEF2C_K4Q,
where Lys4 is substituted with arginine or glutamine. The
K4R mutation prevents acetylation and retains the
positive charge of the lateral chain, thus mimicking a
permanent deacetylated status. On the contrary, the
substitution with a glutamine residue (K4Q) approximates
the physical changes associated with acetylation. We
observed that the K4R mutant exhibits substantially the
same activity as the wt protein (Figure 4A, lane 6 versus
lane 2). This is not surprising since MEF2C from
reticulocyte lysates is probably not acetylated. On
the contrary, as shown in lane 7, the K4Q mutant exhibits
a strongly enhanced DNA-binding activity compared to
the wt protein (at least 7-fold higher as evaluated by a
PhosphorImager analysis, data not shown). We next
investigated if Lys4 acetylation alters the DNA-binding
properties of the MEF2C protein ectopically expressed
in transfected cells in culture. COS1 cells were transfected
with expression vectors encoding wt MEF2C or the K4R
mutant. As shown in Figure 4B, the K4R mutant
binds DNA less eﬃciently than wt MEF2C (compare
lanes 3 and 2).
FRAP assay. The eﬀect of Lys4 acetylation on the kinetic
properties of MEF2–DNA interaction in the chromatin
context of a living cell, were then explored by the
FRAP technique. FRAP experiments were performed in
C2C7 cells, proliferating or stimulated to diﬀerentiate for
24 h, transiently transfected with wt or Lys4 mutant
GFP-MEF2C. To investigate the contribution of Lys4
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Figure 3. MEF2C is acetylated in vitro and in vivo. (A) Wild-type (WT)
His6MEF2C1-92, or the mutant where the Lys4 residue is substituted
with an arginine (K4R) fusion proteins consisting of the
MADS box and the MEF2 domains of MEF2C fused to the His6
tag, were analysed by gel electrophoresis after in vitro acetylation in the
reaction buﬀer alone (lanes 1 and 4), containing the p300 enzyme
puriﬁed from baculovirus (lanes 2 and 5) or containing the p300
enzyme and the p300-speciﬁc inhibitor LysCoA (lanes 3 and 6,
respectively). Equivalent amounts of the acetylation products were
loaded in two distinct gels and analysed respectively with the antisera
that recognizes acetylated lysine residues (anti-AcK) or the His6 tag
(anti His6), (upper and lower panels, respectively). (B) Western blot
analysis of FLAG-MEF2C WT and FLAG-MEF2C_K4R puriﬁed
from transfected COS1 cells by immunoprecipitation with the anti-
FLAG antibody (IP anti-FLAG). Immunoprecipitated proteins were
revealed with the antibodies directed to acetyl lysine (anti-AcK, upper
panel) and to the FLAG epitope (anti-FLAG). Mock-transfected cells
were used as a control (lane 1).
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acetylation to the observed decreased mobility of GFP-
MEF2C in myotubes, we compared GFP-MEF2C_WT
and GFP-MEF2C_K4R. GFP-MEF2C_WT and GFP-
MEF2C_K4R display the same mobility in the nucleus of
proliferating cells (Figure 5A), the t1/2 of the two proteins
being 0.34 s (0.03 s SE) and 0.31 s (0.02 s SE),
respectively (Figure 5D). Upon induction of diﬀerentia-
tion, the mobility of both wt and mutant MEF2C is
decreased, but at a diﬀerent extent: the mobility of the
mutant protein is higher than that of the wt protein
(Figure 5B). In a parallel set of experiments FRAP was
used to determine the mobility of GFP-MEF2C_R3T, a
mutant that was shown to be unable to bind the MEF2
responsive elements, albeit retaining the ability of homo-
and heterodimerizing with other MEF2 members (42).
In diﬀerentiated C2C7 cells, the mobility of GFP-
MEF2C_R3T is signiﬁcantly higher than that of wt
GFP-MEF2C. Figure 5C, which is a merge of the curve
shown in Figure 5B and the curve obtained with the GFP-
MEF2C_R3T protein, indicates that the mobility of
MEF2C_K4R in diﬀerentiating muscle cell nuclei is
intermediate between the two MEF2C proteins which
display the highest (MEF2C_WT) and the lowest
(MEF2C_R3T) DNA-binding aﬃnity. This is reﬂected
by the calculated t1/2 for the three proteins in diﬀerentiat-
ing muscle cells, i.e. 0.37 s (0.02 s SE) for MEF2C_R3T,
0.46 s (0.03 s SE) for MEF2C_K4R and 0.64 s (0.05 s
SE) for MEF2C_WT (Figure 5D, DM 24h). Collectively,
and consistently with the results obtained with EMSA
experiments, these data indicate that Lys4 acetylation is
not a requisite for MEF2 association to DNA, but
increases it at the early stage of muscle cell diﬀerentiation.
Effect of Lys4 acetylation onMEF2C activity
and p300 coactivation
Reporter assays were performed by co-transfecting COS1
cells with wt or mutant MEF2C and a plasmid construct
containing the Luciferase reporter gene under the control
of three MEF2 sites from the Desmin gene regulatory
region. It has been previously shown that p300 physically
interacts with MEF2 proteins and enhances their tran-
scriptional activity (43). To investigate the role played by
the acetylation of Lys4 in mediating the p300 co-
activation of MEF2C-dependent transcription, p300 was
co-transfected in the cells. Figure 6A shows that the K4R
mutation causes a modest, although reproducible, reduc-
tion (35%) of MEF2-dependent transcriptional activity.
Figure 6B is a western blot analysis of the extracts of
transfected cells, showing that the mutant MEF2C protein
is expressed at a level comparable with the wt protein.
We also found that the stability of the mutant protein
is comparable to that of wt MEF2C (data not shown).
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Figure 4. Eﬀect of Lys4 acetylation on MEF2 binding to DNA. (A) An oligonucleotide encompassing the MEF2 site of the MCK enhancer was used
as probe in EMSA assay performed with in vitro translated proteins (IVT). The EMSA assay was performed with the following in vitro translated
proteins: wild-type MEF2C (WT, lanes 2–5), MEF2C_K4R (K4R, lane 6) and MEF2C_K4Q (K4Q, lane 7); the unprogrammed reticulocyte lysate
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The reduced transcriptional activity of the K4R mutant
was observed in myogenic C2C7 and L6 cell lines, as well
as in C3H10T1/2 and NIH 3T3 cells (data not shown).
In addition, the same eﬀect was observed when reporter
transcription was controlled by the MCK enhancer or the
Myogenin proximal control region (data not shown).
These data collectively indicate that the eﬀect of Lys4
modiﬁcation is not dependent on the cell and promoter
context. Interestingly, Figure 6A clearly shows that the
p300-dependent enhancement of MEF2 transcriptional
activity is clearly reduced when MEF2C_K4R is used,
suggesting that Lys4 acetylation substantially contributes
to the co-activation mechanism. The observations that
Lys4 acetylation results in an enhancement of MEF2
DNA-binding properties and that p300 promotes the
acetylation of MEF2 on Lys4 in vitro and in cell culture,
prompted us to investigate if p300 can inﬂuence the DNA-
binding activity of MEF2C. To test this hypothesis we
performed EMSA where a 32P-radiolabelled oligonucleo-
tide representing the MEF2 site from the enhancer of the
MCK gene was incubated with the nuclear extracts of
C2C7 cells alone or added of the P300 enzyme puriﬁed
from baculovirus. As shown in Figure 6C, the addition of
p300 to the C2C7 nuclear extracts cells results in an
enhancement of the endogenous MEF2-dependent DNA-
binding activity. This eﬀect is dependent on the enzymatic
activity of p300, since the p300-speciﬁc enzymatic
inhibitor LysCoA, abolishes it (data not shown). It has
been extensively reported that MEF2 proteins cannot
induce myogenic conversion in transfected ﬁbroblasts,
but, when co-expressed with the myogenic basic helix-
loop-helix (bHLH) proteins, they enhance myogenic
conversion (44). In order to investigate the contribution
of Lys4 acetylation to the MEF2-dependent enhancement
of myogenic conversion, we transfected C3H10T1/2
ﬁbroblasts with MyoD and the expression vectors for
either wt MEF2C or MEF2C_K4R. To evaluate the
extent of myogenic conversion, we measured the expres-
sion level of the sarcomeric protein MyHC by western
blotting followed by densitometric analysis of the signals
associated to MyHC (Figure 6D and E). When wt
MEF2C was co-expressed with MyoD, induction of
myogenesis, assessed after 3 and 5 days in diﬀerentiation
medium, was synergistic: compare lanes 4 and 7 (MyoD
alone) to lanes 5 and 8 (MyoD+MEF2C). On the
contrary, when C3H10T1/2 ﬁbroblasts were cotransfected
with MyoD and the MEF2C_K4R mutant no synergistic
eﬀect was observed, but rather a decrease of the MyHC
signal after 5 days in diﬀerentiation medium: compare
lanes 4 and 7 (MyoD alone) to lanes 6 and 9
(MyoD+MEF2C_K4R). The data presented suggest
that the acetylation of MEF2 proteins on Lys4, speciﬁ-
cally observed in diﬀerentiated muscle cells, contributes
substantially to the increase of the DNA-binding aﬃnity
of MEF2C during muscle diﬀerentiation and thus to
the activation of transcription of muscle-speciﬁc genes.
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Figure 5. FRAP analysis of GFP-MEF2C mutants. (A and B) Fluorescence recovery curves obtained with GFP-MEF2C_K4R (red) and wild-type
GFP-MEF2C (blue) in proliferating (A) and diﬀerentiating (B) C2C7 cells. (C) Fluorescence recovery curves obtained with GFP-MEF2C_R3T
(yellow), GFP-MEF2C_K4R (red) and wild-type GFP-MEF2C (blue) in diﬀerentiating C2C7 cells. (D) Half-life values (time in seconds when
ﬂuorescence intensity in bleached area reaches half of the maximal value) in proliferating (GM) or in diﬀerentiating (DM 24h) C2C7 cells transfected
with wild-type GFP-MEF2C (WT), GFP-MEF2C_K4R (K4R), GFP-MEF2C_R3T (R3T). Reported values are average values SE, obtained from
at least 10 cells in two independent experiments.
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In addition, since p300 acetylates Lys4 in MEF2C, this
might be part of the mechanism at the basis of p300
co-activation of MEF2-dependent transcription.
DISCUSSION
MEF2 proteins play a pivotal role in skeletal and cardiac
myogenesis, as well as in several other important cellular
processes, such as neuronal survival and T-lymphocyte
apoptosis (45). To fulﬁl such a variety of functions,
the activity of MEF2 proteins must be subjected to a
ﬁne regulation that allows them to respond promptly to
various signalling pathways. Several mechanisms contri-
bute to the transcriptional regulation of MEF2 during
myogenesis. They include the interaction with a complex
network of transcriptional co-activators and co-repressors
as well as post-translational modiﬁcations (10,15,46–50).
In the present report, we present evidence for a regulation
of the DNA-binding properties of MEF2C that occurs at
the transition from myoblasts to diﬀerentiating myotubes
and is based on a newly identiﬁed post-translational
modiﬁcation, i.e. Lys4 acetylation. Lys4 acetylation
greatly enhances MEF2 binding to DNA in vitro and to
chromatin in vivo, thus indicating that it might contribute
to the activation of the MEF2-dependent transcriptional
program at the onset of muscle cell diﬀerentiation.
We show that ‘the DNA-binding properties of MEF2
proteins change substantially at the transition from
proliferating to diﬀerentiated C2C7 muscle cells’, a well-
established and reproducible model of myogenesis (25).
Although many mechanisms of regulation of MEF2 have
been well described, most of them modulate the transacti-
vation potential of MEF2 without apparent modiﬁcation
of its DNA-binding activity. Evidence of a regulatory
mechanism for the DNA-binding activity of MEF2 was
suggested in embryonic and fetal muscle cells, where a
DNA-binding activity at the MEF2 site of the MCK
enhancer was observed in nuclear extracts of fetal but not
embryonic muscle cells, in spite of the presence of MEF2
proteins in both extracts. The treatment of the embryonic
myoblast nuclear extracts with a phosphatase inhibitor
restored the MEF2-dependent DNA-binding activity (33).
MEF2A, C and D have similar DNA-binding properties
in vitro and induce comparable transcriptional activation
of reporter genes in transfected cultured cells (8,51–53).
Although the interaction of MEF2 with co-repressors, like
the class II histone deacetylases and Cabin I, involves the
MADS box, several lines of evidence indicate that this
takes place without interfering with the binding of MEF2
to the cognate DNA sequence (54–57). Nevertheless, it is
conceivable that the interaction of MEF2 proteins
with class II HDACs, inhibits the association of MEF2
with co-factors having HAT activity, which render
chromatin more accessible to transcription factors. For
example, it has been recently reported that the binding of
MEF2A to the Glut4 promoter in skeletal muscle in vivo is
activated by exercise. CaMK signalling is involved in this
regulatory mechanism, likely through a disruption of
MEF2/classII HDACs complexes (58). In the past, a
casein kinase II (CKII) phosphorylation site was identi-
ﬁed, that is conserved in the MADS box of all known
MEF2 proteins (59). Phosphorylation of this site drama-
tically enhances the DNA-binding activity of MEF2C.
This site appears to be phosphorylated constitutively
in vivo, with no evidence for regulation. Moreover,
p300-dependent acetylation of MEF2C was observed in
diﬀerentiated C2C12 cells. Surprisingly, the acetylation of
lysine residues outside the MADS box enhances the
binding to the MEF2 site (15). It was suggested that in
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Figure 6. Eﬀect of Lys4 acetylation on MEF2 activity and p300
co-activation. (A) Luciferase reporter activity of COS1 cells co-
transfected with pGL3(desMEF2)3, pRSVb-gal and the empty plasmid
expression vector pcDNAI/Amp or the vectors encoding HA-p300,
MEF2C (WT) and MEF2C_K4R (K4R) alone or in the indicated
combinations. The obtained luciferase activity values were normalized
to b-galactosidase activity and are shown as fold the value obtained
with the empty pcDNAI/Amp expression vector (MEF2C-, p300).
The results shown are the average SD of at least three independent
transfection experiments. (B) Western blot analysis of MEF2 proteins
present in the cell lysates used in the experiments shown in panel A. (C)
An oligonucleotide encompassing the MEF2 site of the MCK enhancer
was used as probe in EMSA assays performed with nuclear extracts
(NE) of C2C7 cells (lane1) and the same extracts incubated with p300
(lane 2). The speciﬁc MEF2–DNA complex is indicated by an arrow.
(D) Myogenic conversion assay of C3H10T1/2 ﬁbroblasts co-trans-
fected with MyoD and either an empty vector, MEF2C_WT or
MEF2C_K4R. After 48 h in GM, cells were allowed to diﬀerentiate in
DM for 3 or 5 days before lysis and analysis of myosin heavy chain
expression by western blot with the speciﬁc antibody. Actin levels were
also determined as a loading control. The results of densitometric
quantiﬁcation of the MyHC bands obtained in the western blot are
reported in panel E. (E) The relative density of each MyHC band is
normalized to the density of the corresponding actin band and is
expressed relative to the amount of MyHC protein in cells transfected
with MyoD alone. The results of two independent experiments were
averaged with the SD indicated.
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cardiomyocytes the novel protein Ki-1/57 physically
interacts with MEF2C and this interaction inhibits the
MEF2C–DNA-binding activity (60). In order to explore
the DNA-binding properties of MEF2 proteins during
muscle diﬀerentiation, we performed a time-course ChIP
experiment that allowed us to establish that MEF2
proteins bind the Myogenin promoter in chromatin only
upon induction of diﬀerentiation of C2C7 myogenic cells
(Figure 1A and C). Similarly, it has been reported that
MEF2 proteins are selectively recruited to an AT-rich
DNA sequence of the MyoD distal enhancer only in
diﬀerentiated C2C12 muscle cells (61).
In this context, FRAP represents an important com-
plementary tool to ChIP to study the dynamic properties
of protein–DNA interactions in living cells (32). By this
technique we could demonstrate that the mobility of
ectopically expressed GFP-MEF2C is highly and repro-
ducibly reduced in diﬀerentiating C2C7 cells: the protein
half-life of GFP-MEF2C was estimated to be 0.64 s in cells
induced to diﬀerentiate for 24 h and 0.34 s in proliferating
myoblasts, indicating that MEF2 proteins bind more
stably to DNA upon induction of diﬀerentiation
(Figure 1D and E). The decrease of GFP-MEF2C
mobility in diﬀerentiating cells is mainly due to the
interaction with DNA, since a similar eﬀect was not
observed with the MEF2C_R3T mutant that is unable to
bind DNA.
The increased aﬃnity of MEF2 for DNA at the onset of
muscle cell diﬀerentiation correlates with the observation
that, as shown by mass spectrometry analysis, ‘MEF2C is
acetylated on Lys4 only in diﬀerentiated muscle cells’
(Figure 2A). Several recent reports demonstrated that
MEF2 proteins are a target for acetylation. Zhao et al. (19)
showed that Lys424 inMEF2D is subjected alternatively to
sumoylation and acetylation that result respectively in the
repression or activation of MEF2. Analogous results were
reported for the corresponding lysine of MEF2A (50). Ma
et al. (15) described several MEF2C acetylated residues
only in diﬀerentiated muscle cells, which are located in the
C-terminal region of the protein (Lys116, Lys 119, Lys 234,
Lys 239, Lys 252 and Lys 264) and thus are unlikely to
modulate MEF2 binding to DNA. Our mass spectrometry
analysis of MEF2C, ectopically expressed in C2C7 cells,
did not reveal peptides with masses expected from the
acetylation events reported in the literature (15,19,50). On
the contrary, we did observe the peptides corresponding to
the unmodiﬁed residues. These discrepancies are possibly
due to the fact that the acetylated peptides do not eﬃciently
ionize or, alternatively, that the percentage of acetylated
residues is too low to be revealed in our experimental
conditions. In addition, acetylation of some of the residues,
interfering with trypsin digestion, may result in the
generation of peptides too large to be analysed. The
acetylation events on MEF2 proteins summarized above
take place in the C-terminus, thus they unlikely modulate
the MEF2 DNA-binding properties. On the contrary,
‘Lys4 acetylation strongly enhances the DNA-binding
activity of MEF2’, as we observed in EMSA experiments
performed with the in vitro translated protein bearing the
K4Q mutation, which mimics permanent acetylation, and
in FRAP experiments with theGFP-MEF2C_K4Rmutant,
which does not allow Lys4 acetylation. Moreover, we show
that MEF2C ectopically expressed in COS1 cells binds
DNA less eﬃciently when Lys4 is substituted with arginine.
The contribution of Lys4 acetylation to the high-aﬃnity
binding of MEF2C to its chromatin sites can be inferred
by the behaviour of the non-acetylatable MEF2C_K4R
mutant in FRAP experiments, which shows a higher
mobility than wt MEF2C in diﬀerentiating muscle cells
(protein half-life of 0.46 and 0.64 s for the MEF2C_K4R
mutant and the wt protein, respectively). Lys4 acetylation
does not represent a prerequisite for MEF2C binding to
chromatin: the K4R mutant still exhibits a mild but
signiﬁcant reduction of its mobility in diﬀerentiating
muscle cells (the half-life of 0.31 s in myoblasts is prolonged
to 0.46 s in cells stimulated to diﬀerentiate). Coherently
with these observations, Lys4 is located in the MADS box,
the MEF2 domain directly involved in DNA binding,
which is conserved in all MEF2 proteins and it was shown
to play a role in determining the DNA-bending properties
of MEF2 (62). The crystal and solution structures of the
MEF2A–DNA complex have been solved, revealing that
Lys4 interacts with the phosphodiester backbone to push
the Arg3 side chain into the DNA minor groove (40,41).
Lys4 acetylation neutralizes the side-chain positive charge
involved in the interaction with DNA, however it enhances
the DNA-binding aﬃnity of MEF2C. The NMR analysis
of the complex indicates that Lys4 establishes hydrophobic
contacts with DNA, therefore it can be hypothesized that
these contacts are stabilized by the acetylation event or,
alternatively, that acetylated Lys4 mediates the interaction
of MEF2C with additional co-factors resulting in a higher
aﬃnity DNA binding. Collectively, these data indicate that
Lys4 acetylation is required for achieving the high DNA-
binding aﬃnity that is necessary for a prompt ﬁring of the
MEF2-dependent transcriptional programme in diﬀeren-
tiating muscle cells. In order to evaluate the functional role
of Lys4 acetylation of MEF2C, we performed transactiva-
tion and myogenic conversion assays.
Indeed we show that the ‘MEF2C_K4R mutant exhibits
a weak but reproducible reduction (30%) of its transcrip-
tional activity in comparison with the wt MEF2C protein
in transactivation assays’ (Figure 6A) more importantly,
the co-activation of MEF2 mediated by p300 depends
on the presence of Lys4, since the activity of the mutant
protein K4R is not enhanced by p300 in transactivation
assays.
We do not know which enzymes are responsible for the
acetylation of Lys4. It has been reported that p300
acetylates the C-terminus of MEF2C in vivo (15). The
observations that: (i) p300 promotes the acetylation of
Lys4 in MEF2C in vitro and in vivo; (ii) p300 directly
enhances the DNA-binding aﬃnity of MEF2C in EMSA;
(iii) p300 co-activation of MEF2C transcriptional activity
requires an intact Lys4 residue, together with the role
played by this co-activator in muscle cell diﬀerentiation
(63,64), collectively indicate p300 as a likely candidate for
directly acetylating MEF2 proteins. In keeping with this
hypothesis, we observed that p300 associates to chromatin
on the same Myogenin gene DNA regulatory region that
is bound by MEF2 (data not shown). This physical
proximity could allow p300-dependent acetylation of
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MEF2C and thus stabilization of MEF2–DNA
interactions.
The DNA-binding domain of MEF2 also mediates the
interaction of MEF2 proteins with the myogenic bHLH
proteins and thus their cooperation in promoting skeletal
muscle diﬀerentiation (44). Thus, we investigated if Lys4
acetylation is involved in regulating the MEF2-MyoD
synergy by performing myogenic conversion assays. As
shown in Figure 6D and E we observed that lack of
acetylation on Lys4 abolishes the functional interaction
between MyoD and MEF2C, since the co-expression of
MyoD and the mutant protein MEF2C_K4R does not
result in an enhancement of myogenic conversion. On the
contrary, we observed a decrease of MyHC expression,
suggesting that the MEF2C_K4R mutant could behave as
a dominant negative protein. The eﬀect of MEF2C_K4R
on MyHC expression is coherent with recent reports
showing that MEF2 proteins are required for the correct
expression of thick ﬁlament proteins and for muscle
sarcomere integrity (6,7). We propose a model where
MEF2 proteins are maintained functionally silent in
myoblasts, by deacetylation of Lys4 and other lysine
residues. Deacetylated MEF2 binds DNA with lower
aﬃnity, even though is still able to recognize its cognate
DNA sites and thus to locate in the appropriate chromatin
domains. A change of the equilibrium towards the MEF2
acetylated form, more stably bound to chromatin, induced
directly or indirectly by p300, would cause the prompt and
eﬃcient ﬁring of MEF2 transcriptional activity, in
coincidence with the induction of muscle cell diﬀerentia-
tion. It has been recently shown that the class I histone
deacetylase HDAC3 physically interacts with MEF2
proteins and deacetylates them, moreover HDAC3
associates to the same DNA sequence on chromatin that
are contacted by MEF2 (65). Upon induction of skeletal
muscle diﬀerentiation, the MEF2/HDAC3 association is
strongly reduced by a regulatory mechanism that still
needs to be clariﬁed. In addition to HDAC3, it has been
widely described a mechanism of negative regulation of
MEF2 activity by the class II HDACs 4/5/7/9. These
deacetylases have not been shown to directly decetylate
MEF2 proteins but they could contribute indirectly to
maintain the deacetylated status of MEF2 proteins, by
recruiting class I HDACs or by regulating the activity of
p300. Class II HDACs associate with MEF2 proteins in
C2C7 myoblasts; during skeletal muscle diﬀerentiation
they are phosphorylated and translocate to the cytoplasm.
Class I and class II deacetylases interact with the DNA-
binding domain of MEF2, as well as p300, suggesting a
mutual exclusive association. We suggest that the regula-
tion of MEF2 acetylation, and thus of its DNA-binding
activity, concerns HATs as well as HDAC3 and HDAC4/
5/9 localization and activity and that Lys 4 is a nodal
target for HATs and HDACs during myogenesis.
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